INC Research and Debiopharm agree partnership
INC will manage clinical study for Swiss firm
INC Research, a US-based contract research organisation (CRO), has agreed to manage a clinical study for Swiss biopharmaceutical group Debiopharm. The project is linked to an important project in Debiopharm’s pipeline.
The two companies have also agreed a framework partnership in which INC Research, based in Raleigh, North Carolina, will conduct future clinical studies for Debiopharm.
INC Research offers a range of services, which can include complete management of a compound or therapeutic area; management of a specific function or set of critical processes; sharing in the risk and reward of a compound's performance; or acting as the sole source development partner for a customer.
The company recently bought Kendle International of Cincinnati for US$232m, broadening its operations to meet Phase I-IV clinical development needs and increasing its workforce to 5,000 across six continents.
Debiopharm Group in-licences, develops and/or co-develops biological and small molecule drug candidates having reached clinical development phases I, II or III as well as earlier-stage candidates.
